Connect with us

Newsletters

The Capitalist Newsletter – October 31, 2016

Published

on

TWITTER SHUTTERS VINE BEFORE ANNOUNCING JOB CUTS; IS THIS THE END OF TWITTER?

When Twitter acquired Vine in 2012 in an attempt to bring video to social media, hopes were high. Twitter was thriving with an ever expanding user base and Vine was all the rage. The $30 million price tag seemed like a steal. Now, Twitter is officially closing vine down. Is this a sign of things to come? Can Twitter be far behind?

Read The Capitalist’s Take Here

Read More at CNN

Read More at Techcrunch


DRAFTKINGS & FANDUEL FINALIZING TERMS OF IMMINENT MERGER

DraftKings and FanDuel, the two dominant players in the daily fantasy sports industry, are finalizing terms of a merger, multiple sources with knowledge of the discussions told ESPN on Friday.

Read More From ESPN Here

Read More From ABC Here

Raven_Steel_Ad-V2
Raven_Steel_Ad-05

Read More From Recode Here


ARMED OCCUPANTS OF OREGON WILDLIFE REFUGE ACQUITTED

In a surprise verdict, a jury has found all seven defendants not guilty of charges linked to their 41-day, armed occupation of Oregon’s Malheur National Wildlife Refugeearlier this year. The courtroom quickly descended into chaos…

Read More From NPR Here

Read More From NY Times Here

Read More From US News Here


Closing Bell

-Friday, October 28th

Stocks Close Lower After New Clinton Probe Opens

Big Insider Trades

– Alphabet Inc. (GOOG) CEO Larry Page Sells $27m

– Freeport-McMoRan, Inc. (FCX) Director Courtney Mather Buys $1.6m

Winners & Losers

– Gravity Co., Ltd. (GRVY) Skyrockets UP (115.38%) After Stellar Q3 Earnings Report

– Opexa Therapeutics, Inc. (OPXA) Plummets DOWN (69.12%) After Phase 2 Trial Misses Endpoint

The TIP Sheets

– Friday, October 28th

– McKesson Corporation (MCK) Falls Down (22.67%) on Disappointing Quarterly Results and Downbeat Outlook for Future Drug Prices. Shares Should Continue DOWN

Unusual Volume

– Amgen, Inc. (AMGN) Tumbles DOWN (9.58%) on 18m Shares Traded After Relatively Strong Financial Results Take a Back Seat to Flagship Drug’s Future Pricing Problems. Investors Fear the Company Will Struggle to Replace Lost Revenues. Look For Shares to Bounce Back UP

Click to comment

Leave a Reply

Your email address will not be published.

Continue Reading

Subscribe To Our Newsletter:



Copyright © 2020 The Capitalist. his copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.

[email]
[email]